Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX1 | Q9Y5S8 | 13/20 | 1.00 |
| ▸ | MAPT | P10636 | 10/20 | 1.00 |
| ▸ | GAA | P10253 | 9/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | SNCA | P37840 | 2/20 | 1.00 |
| ▸ | CYBB | P04839 | 1/20 | 1.00 |
| ▸ | APP | P05067 | 1/20 | 1.00 |
| ▸ | NOX3 | Q9HBY0 | 1/20 | 1.00 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenothiazine SCHEMBL28073776 | 1.00 | NOX1 (1.00) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL342449 | 1.00 | NOX1 (1.00) | NOX1MAPTGAAMEN1KMT2A | |
| Ethylene SCHEMBL10370327 | 0.97 | NOX1 (0.94) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL12311060 | 0.90 | NOX1 (0.82) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL3580166 | 0.85 | NOX1 (0.74) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL3586011 | 0.85 | NOX1 (0.74) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL31491519 | 0.85 | NOX1 (0.74) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL17284839 | 0.83 | NOX1 (0.71) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL24220378 | 0.83 | NOX1 (0.70) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL9778312 | 0.83 | NOX1 (0.70) | NOX1MAPTGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744663-A2 | SKIN COMPOSITION | Eaderm Co., Ltd. (JP) | 2026-05-20 | — | — | EP | claimed |
| EP-4739298-A1 | ACTIVATORS OF THE XC- SYSTEM AND/OR GPX-4 FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2026-05-13 | — | — | EP | claimed |
| WO-2025075611-A1 | ULTRASONIC INDICATOR BASED ON EMULSION FORMATION | JP LABORATORIES, INC. (US) | 2025-04-10 | — | — | WO | claimed |
| EP-4205750-B1 | NADPH OXIDASE INHIBITOR FOR SUPPRESSING OR IMPROVING HAIR LOSS OR TREATING ALOPECIA | EADERM CO LTD (JP) | 2025-04-09 | — | — | EP | claimed |
| US-12239655-B2 | Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents | EMORY UNIVERSITY (US) | 2025-03-04 | — | — | US | claimed |
| WO-2025012667-A1 | ACTIVATORS OF THE XC-SYSTEM AND/OR GPX-4 FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION. | SORBONNE UNIVERSITE (FR) | 2025-01-16 | — | — | WO | claimed |
| WO-2025012137-A1 | ACTIVATORS OF THE XC- SYSTEM AND/OR GPX-4 FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2025-01-16 | — | — | WO | claimed |
| CN-118079006-A | Skin composition | 国立大学法人东京医科齿科大学 | 2024-05-28 | — | — | CN | claimed |
| US-11814623-B2 | Methods of treating a wound using epigenetic regulation | UNIVERSITY OF MASSACHUSETTS (US) | 2023-11-14 | — | — | US | claimed |
| EP-4205750-A1 | COMPOSITIONS FOR SUPPRESSING OR IMPROVING HAIR LOSS AND GRAYING, AND USES THEREOF | National University Corporation Tokyo Medical and Dental University (JP) | 2023-07-05 | — | — | EP | claimed |
| US-20220331389-A1 | SKIN COMPOSITION | EADERM CO., LTD. (JP) | 2022-10-20 | — | — | US | claimed |
| US-11298372-B2 | Composition for ameliorating loss of hair and graying of hair, and use thereof | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) | 2022-04-12 | — | — | US | claimed |
| EP-3978020-A1 | SKIN COMPOSITION | National University Corporation Tokyo Medical and Dental University (JP) | 2022-04-06 | — | — | EP | claimed |
| EP-4744663-A2 | SKIN COMPOSITION | Eaderm Co., Ltd. (JP) | 2026-05-20 | — | — | EP | disclosed |
| EP-3856736-B1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-05-06 | — | — | EP | disclosed |
| US-12599660-B2 | Therapeutic RNA for HPV-positive cancer | BiòNTech SE (DE) | 2026-04-14 | — | — | US | disclosed |
| EP-3978020-A1 | SKIN COMPOSITION | National University Corporation Tokyo Medical and Dental University (JP) | 2022-04-06 | — | — | EP | disclosed |
| CN-114269378-A | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for the treatment of cancer | 安斯泰来制药股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-114026067-A | Peptide mimetics for the treatment of coronavirus and picornavirus infections | 埃默里大学 | 2022-02-08 | — | — | CN | disclosed |
| US-20220033379-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599660-B2 | Therapeutic RNA for HPV-positive cancer | UPF1, NSUN2, RNGTT | NOX1 2369/4885MAPT 3225/4885GAA 3898/4885 |
| US-12239655-B2 | Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents | NOX1, NOX3, NOX4 | NOX1 1/4885MAPT 1860/4885GAA 901/4885 |
| US-20220033379-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CYBB, NOX1, NOX4 | NOX1 2/4885MAPT 2492/4885GAA 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.